05-3280. Oral Dosage Form New Animal Drugs; Ivermectin Paste  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for oral use of ivermectin paste in horses for treatment and control of various internal parasites or parasitic conditions.

    DATES:

    This rule is effective February 22, 2005.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Lonnie W. Luther, Center for Veterinary Start Printed Page 8514Medicine (HFV-104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-8549, e-mail: lonnie.luther@fda.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed ANADA 200-326 for BIMECTIN (ivermectin) Paste 1.87%. The application provides for oral use of 1.87 percent ivermectin paste in horses for the treatment and control of various species of internal parasites or parasitic conditions. Cross Vetpharm Group's BIMECTIN Paste 1.87% is approved as a generic copy of Merial Limited's EQVALAN Paste, approved under NADA 134-314. ANADA 200-326 is approved as of January 19, 2005, and 21 CFR 520.1192 is amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.

    In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

    The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects in 21 CFR Part 520

    • Animal drugs
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

    End Amendment Part Start Part

    PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 520 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority Start Amendment Part

    2. Section 520.1192 is amended by adding paragraphs (b)(3) and (e)(1)(ii)(C) to read as follows:

    End Amendment Part
    Ivermectin paste.
    * * * * *

    (b) * * *

    (3) No. 061623 for use of a 1.87 percent paste for use as in paragraph (e)(1)(i), (e)(1)(ii)(C), and (e)(1)(iii) of this section.

    * * * * *

    (e) * * *

    (1) * * *

    (ii) * * *

    * * * * *

    (C) Large strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, and Triodontophorus spp. including T. brevicauda and T. serratus; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp. including C. catinatum and C. pateratum, Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus spp., and Cylicostephanus spp. including C. calicatus, C. goldi, C. longibursatus, and C. minutus; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp. including G. intestinalis and G. nasalis; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca sp.

    * * * * *
    Start Signature

    Dated: February 8, 2005.

    Stephen F. Sundlof,

    Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 05-3280 Filed 2-18-05; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
2/22/2005
Published:
02/22/2005
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
05-3280
Dates:
This rule is effective February 22, 2005.
Pages:
8513-8514 (2 pages)
PDF File:
05-3280.pdf
CFR: (1)
21 CFR 520.1192